



COVID-19 Vaccine Planning Healthcare Call #4

2020.12.04



Presenters

Candice Robinson, MD, MPH
Medical Director, Immunizations

Elisabeth Weber, MA, RN, NHDP-BC
Projects Administrator, Hospital Preparedness Program

Chicago Department of Public Health



Agenda

- Vaccine Timeline
- Vaccine prioritization
- Staff Vaccination Inquiry
- Provider enrollment update
- Vaccine safety monitoring
- Training materials and resources
- Website



Recent COVID-19 Vaccine Announcements

- Pfizer and Moderna have requested emergency use authorization for COVID-19 vaccines to FDA
- FDA advisory committee to meet and discuss both vaccines
 - December 10th Pfizer vaccine
 - December 17th Moderna vaccine

<https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study>

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization>

<https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement>

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-second-covid-19-vaccine>


December 2020



Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
		1	2	3	4	5
6	7	8	9	10 FDA meets: Pfizer EUA	11 CDC/ACIP meet?	12
13 CDC/ACIP recommend?	14	15 First doses of Pfizer vaccine potentially arrive in Chicago	16	17 FDA meet: Moderna EUA	18 CDC/ACIP meet?	19
20 CDC/ACIP recommend?	21	22 First doses of Moderna vaccine potentially arrive in Chicago	23	24	25	26
27	28	29	30	31		

★ Vaccine Prioritization

- Initial supplies of COVID-19 vaccine will be limited
 - Requires vaccine prioritization plans
- CDPH current plans based on the national guidance
 - National Academies of Sciences
 - Advisory Committee on Immunization Practices (ACIP)
- Healthcare personnel (HCP) first population recommended to receive vaccine







Figure 2-S in National Academies of Sciences, Engineering, and Medicine. 2020. *Framework for equitable allocation of COVID-19 vaccine*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25917>.)

Update: ACIP recommendations

Proposed Interim Phase 1 Sequence



Who are considered HCP

- **Healthcare personnel (HCP)** refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air. These HCP may include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the health care facility, and persons (e.g., clerical, dietary, environmental services, laundry, security, maintenance, engineering and facilities management, administrative, billing, and volunteer personnel) not directly involved in patient care but potentially exposed to infectious agents that can be transmitted among from HCP and patients.

CDPH released *considerations* for prioritization among Healthcare Personnel (HCP) to hospitals

Initial Vaccine Prioritization Considerations:

- Tier 1 – HCP routinely caring for COVID-19 patients/patients under investigation (PUIs) AND performing or attending aerosol generating procedures (AGP).
- Tier 2 – HCP that may care for COVID-19 patients/PUIs and perform or attend AGPs.
- Tier 3 – HCP that provide direct care to COVID-19 patients/PUIs but do not generally perform or attend AGPs.
- Tier 4 – HCP with direct contact with material potentially contaminated with COVID-19 viral particles (depending on hospital protocols, could include phlebotomists, technicians, environmental and dietary services personnel).
- Tier 5 – HCP that provide direct patient care to patients who are at low risk of COVID-19 and persons with indirect exposure to patients or infectious materials.

Vaccine Sub-prioritization Considerations:

- Personnel 60 years of age and older
- Personnel with underlying health conditions who are at increased risk of severe COVID-19 disease

In addition, hospitals may also take into account other factors, including but not limited to mitigation of health inequities, the importance of expeditiously achieving high levels of vaccine coverage among front line staff, and facility level epidemiologic assessment of exposure risk.



Chicago Department of Public Health COVID-19 Vaccine Planning

- Vaccine will be allocated to hospitals for vaccination of employees
- All doses allocated in the first 21 or 28 days (depending on vaccine) are intended for use as the first dose in the series
- Hospitals do NOT need to hold half of the vaccine allocation for second doses
- 2nd doses are being held at the federal level
- CDPH will communicate with hospitals when a vaccine allocation contains doses intended for 2nd dose use.

Staff Vaccination Inquiry Survey

- Vaccination of healthcare personnel not associated with a hospital or health system

Outpatient clinics	Dental clinics
Homecare staff	Mortuary services/funeral home staff
Dialysis centers	Urgent care facilities
Independent pharmacies	

- Complete the staff vaccination inquiry survey
 - <https://redcap.link/StaffVaccinationSurvey>
- CDPH will follow-up to provide vaccination options for staff




VaccineFinder's role in the COVID-19 Response

- **The COVID-19 Vaccination Program Provider Agreement requires providers to report vaccine supply information as directed by CDC**
- **All COVID-19 vaccination providers must report COVID-19 vaccine inventory daily into VaccineFinder**
- **Option to make location publicly visible during later vaccination phases**
 - Once there is enough supply, COVID-19 vaccination providers may choose to make their location visible on VaccineFinder, making it easier for the public to find provider locations that have COVID-19 vaccine available.
 - CDC will be directing the public to use VaccineFinder to find locations offering COVID-19 vaccine.

★ VaccineFinder Account Set-up

- Email from vaccinefinder@auth.castlighthealth.com
- Click the “Create Account” link to complete VaccineFinder onboarding



COVID Locating Health
POWERED BY Castlight

Create Account


Create an account to report your vaccine inventory. Start by selecting a password.

Email

healthychicago@cityofchicago.org

Password

Confirm Password



VaccineFinder **COVID Locating Health**
POWERED BY Castlight

Complete Registration

Dear [FIRST NAME],

As an entity enrolled in the COVID-19 Vaccination Program, you will need to report on-hand COVID-19 vaccine inventory to the CDC daily using VaccineFinder. VaccineFinder's COVID Locating Health Provider Portal will help you do this.

Here's what you need to do:

1. Create an account to complete registration in 7 days. This is a personalized link that will expire after this time.
2. Log in each day and enter your data no later than midnight local time.

[Create Account](#)

i You must use **Chrome** or **Safari** browsers to access the Provider Portal. Link expires after one click.

Questions? Contact our Support team at VaccineFinder@castlighthealth.com

★ VaccineFinder Account Set-up

- Account set-up email will be sent to the organizational email address provided in Section A of the Provider Agreement
- This may be the CEO or CMO rather than the primary vaccine coordinator
- If you need to change the organization email address from what was previously submitted, please email us at COVID19vaccine@cityofchicago.org

Section A. COVID-19 Vaccination Program Provider Requirements and Legal Agreement

Organization identification

Organization's legal name:

Number of affiliated vaccination locations covered by this agreement:

Organization telephone:

Email: *(must be monitored and will serve as dedicated contact method for the COVID-19 Vaccination Program)*

Street address 1: Street address 2:


City: County: State: ZIP:

VaccineFinder Account Set-up

- Organizations will determine whether they will:
 - report daily on-hand inventory on behalf of all their provider locations (e.g., a clinic headquarters office reporting on behalf of satellite clinics), or
 - individual provider locations will be responsible for reporting this information
- Once a determination is made, it must be maintained for the duration of the COVID-19 Vaccination Program.

Reporting Inventory

- When vaccines are available, providers will log into the provider portal to submit daily COVID-19 vaccine inventory reports for their location(s) via online form or batch upload.



The screenshot shows a web interface for "COVID Locating Health". The main heading is "Update Vaccine Inventory". Below this heading are two buttons: "Upload File" (highlighted in blue) and "Log Manually". The interface is divided into three steps:

- Step 1:** Download an inventory spreadsheet. At the bottom of this step is a link "Blank template" with a download icon.
- Step 2:** Update the spreadsheet with your current inventory. Save and rename the file to include today's date.
- Step 3:** Drag & drop today's spreadsheet here. Or browse to upload your file. Below this text is a "Browse" link and a large "Upload" button.



Resources

- **CDC COVID-19 Vaccination Provider Support, Data and Reporting:**
<https://www.cdc.gov/vaccines/covid-19/vaccination-provider-support.html>
- **VaccineFinder COVID-19 Vaccine Provider Information website (includes video trainings):** <https://vaccinefinder.org/covid-provider-resources>

Provider Enrollment Update

- On Friday, December 4th, enrollment will be open to all providers via I-CARE (Illinois Comprehensive Automated Immunization Registry Exchange).
- Interested providers must submit the CDC COVID-19 Vaccination Program Provider Agreement in I-CARE. Please reach out to us if you need assistance accessing your I-CARE account.
 - If your facility does not have an I-CARE account, you will need apply for an I-CARE account with the Illinois Department of Public Health. Directions will be sent after this call.
- Step-by-step instructions on completing COVID-19 provider enrollment in I-CARE will be sent after this call.
- **Hospitals** that previously enrolled sites in REDCap, do not need to complete the COVID-19 provider enrollment in I-CARE. CDPH completed the COVID-19 enrollment in I-CARE for these sites.

COVID-19 Vaccine Safety Monitoring

- VAERS
 - Per the provider enrollment agreement:
 - “Organization must report any adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS) (1-800-822-7967 or <http://vaers.hhs.gov/contact.html>).”
- V-SAFE
 - New CDC text-based system

VAERS is the nation's early warning system for vaccine safety



VAERS

Vaccine Adverse Event Reporting System

Co-managed by
CDC and FDA

<http://vaers.hhs.gov>

VAERS Vaccine Adverse Event Reporting System
www.vaers.hhs.gov

About VAERS

Report an Adverse Event

VAERS Data

Resources

Submit Follow-Up Information

Have you had a reaction following a vaccination?

1. Contact your healthcare provider.
2. Report an Adverse Event using the VAERS online form or the new downloadable PDF. *New!*

Important: If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. CDC and FDA do not provide individual medical treatment, advice, or diagnosis. If you need individual medical or health care advice, consult a qualified healthcare provider.

¿Ha tenido una reacción después de recibir una vacuna?

1. Contacte a su proveedor de salud.
2. Reporte una reacción adversa utilizando el formulario de VAERS en línea o la nueva versión PDF descargable. *Nuevo!*



What is VAERS?



REPORT AN ADVERSE EVENT

Report significant adverse events after vaccination.



SEARCH VAERS DATA

Download VAERS Data and search the CDC WONDER database.



REVIEW RESOURCES

Find materials, publications, learning tools, and other resources.



SUBMIT FOLLOW-UP INFORMATION

Upload additional information related to VAERS reports.

★ VAERS Covers the Entire U.S. Population



- **320 million U.S. residents** as a covered population for safety monitoring
- All ages, races, states/jurisdictions, healthy people, those with co-morbidities, etc.



- **40-50 thousand total U.S. reports** received each year

VAERS



How to Report an Adverse Event to VAERS

- Go to vaers.hhs.gov
- Submit a report online

For help:

call
[1-800-822-7967](tel:1-800-822-7967)

email
info@VAERS.org

video instructions
<https://youtu.be/sbCWhcQADFE>

VAERS Vaccine Adverse Event Reporting System
www.vaers.hhs.gov

About VAERS | Report an Adverse Event | VAERS Data | Resources | Submit Follow-Up Information

Have you had a reaction following a vaccination?

1. Contact your healthcare provider.
2. Report an Adverse Event using the VAERS online form or the new downloadable PDF. *New!*

Important: If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. CDC and FDA do not provide individual medical treatment, advice, or diagnosis. If you need individual medical or health care advice, consult a qualified healthcare provider.

¿Ha tenido una reacción después de recibir una vacuna?

1. Contacte a su proveedor de salud.
2. Reporte una reacción adversa utilizando el formulario de VAERS en línea o la nueva versión PDF descargable. *Nuevo!*



What is VAERS?

REPORT AN ADVERSE EVENT
Report significant adverse events after vaccination.

SEARCH VAERS DATA
Download VAERS Data and search the CDC WONDER database.

REVIEW RESOURCES
Find materials, publications, learning tools, and other resources.

SUBMIT FOLLOW-UP INFORMATION
Upload additional information related to VAERS reports.



V-SAFE


- Vaccine safety has been and will continue to be one of CDC's top priorities.
- Once COVID-19 vaccines are made available in the United States, CDC will rely on existing systems and a new system, **v-safe**, to monitor vaccine safety.
- **V-safe** is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after someone receives a COVID-19 vaccination
- Through **v-safe**, vaccine recipients can quickly tell CDC if they have any side effects after getting the COVID-19 vaccine.
- Depending on their responses, CDC may follow up with them by phone to get more information. **V-safe** will also remind them to get their second COVID-19 vaccine dose, if needed.

★ Timing of Health Check-ins

- V-safe conducts electronic health check-ins with vaccine recipients
 - daily for first week post-vaccination; weekly thereafter until 6 weeks post-vaccination
 - additional health checks at 3-, 6-, and 12-months postvaccination
 - timeline resets at 2nd dose

V-SAFE

- CDC is requesting that healthcare providers give patients a **v-safe** information sheet at the time of vaccination and encourage them to enroll and fill out the surveys when prompted to do so.
- The information sheet explains **v safe** and provides step-by-step instructions on how to sign up to participate.
- Vaccine recipients can use the QR code or URL on this information sheet to sign up at their convenience.



What is v-safe?

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through **v-safe**, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you. And **v-safe** will remind you to get your second COVID-19 vaccine dose if you need one.

Your participation in CDC's **v-safe** makes a difference—it helps keep COVID-19 vaccines safe.

How can I participate?

Once you get a COVID-19 vaccine, you can enroll in **v-safe** using your smartphone. Participation is voluntary and you can opt out at any time. You will receive text messages from **v-safe** around 2pm local time. To opt out, simply text "STOP" when **v-safe** sends you a text message. You can also start **v-safe** again by texting "START."

How long do v-safe check-ins last?

During the first week after you get your vaccine, **v-safe** will send you a text message each day to ask how you are doing. Then you will get check-in messages once a week for up to 5 weeks. The questions **v-safe** asks should take less than 5 minutes to answer. If you need a second dose of vaccine, **v-safe** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well. You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

Is my health information safe?

Yes. Your personal information in **v-safe** is protected so that it stays confidential and private.*

*To the extent v-safe uses existing information systems managed by CDC, FDA, and other federal agencies, the systems employ strict security measures appropriate for the data's level of sensitivity. These measures comply, where applicable, with the following federal laws, including the Privacy Act of 1974; standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA); the Federal Information Security Management Act, and the Freedom of Information Act.

12/01/20



Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.



Sign up with your smartphone's browser at vsafe.cdc.gov

OR

Aim your smartphone's camera at this code





CDC COVID-19 Vaccination Resources for HCP Webpage

- One-stop website for clinical materials and resources for COVID-19 vaccination.

The screenshot shows the CDC's dedicated webpage for healthcare professionals (HCP) regarding COVID-19 vaccination. The header includes the CDC logo and navigation links. The main heading is 'Healthcare Professionals: Preparing for COVID-19 Vaccination'. A large image of healthcare workers in blue scrubs is featured. Below this, the page is organized into sections: 'Training and Educational Materials' which includes links to a 'Vaccine Storage and Handling Toolkit', a 'COVID-19 Vaccine Training Module For Healthcare Professionals', and 'COVID-19 Vaccination Training Programs and Reference Materials for Healthcare Professionals'. A grid of five resource cards is displayed at the bottom, each with an icon and a title: 'Preparing to Provide COVID-19 Vaccines', 'Making a Strong Recommendation for COVID-19 Vaccination', 'Talking to Patients about COVID-19 Vaccines', 'Answering Patients' Questions', and 'Understanding and Explaining mRNA COVID-19 Vaccines'.

<https://www.cdc.gov/vaccines/covid-19/hcp/index.html>

★ COVID-19 Vaccination Training Programs & Reference Materials

- Comprehensive list of COVID-19 vaccination clinical trainings and materials
- Updated as new programs and materials are added

COVID-19 Vaccination Training Programs & Reference Materials



Find a list of immunization training and educational materials, including basic and COVID-19-vaccine-specific information.

Storage and Handling Toolkit COVID-19 Addendum

- Updated to include storage and handling best practices for COVID-19 vaccines.
- Will be updated with specific information for each COVID-19 vaccine product when available.

Vaccine Storage and Handling Toolkit

The 2020 Vaccine Storage and Handling Toolkit is a comprehensive guide that reflects best practices for vaccine storage and handling from Advisory Committee on Immunization Practices (ACIP) recommendations, product information from vaccine manufacturers, and scientific studies.


The toolkit has been updated for 2020 to clarify language including:

- Beyond use date (BUD)
- Routine maintenance for vaccine storage units
- New definition added to the glossary

The toolkit also contains a COVID-19 Vaccine Storage and Handling Addendum with information on storage and handling best practices for COVID-19 vaccines. This addendum will be updated with specific storage and handling information for each COVID-19 vaccine product. Please sign up for email alerts on this page to be notified when updates are made or check this website often.

★ COVID-19 Vaccine Training: General Overview of Immunization Best Practices for Healthcare Professionals

- Web-based, on-demand training for healthcare professionals outlining best practices when preparing to administer COVID-19 vaccine.



COVID-19 Vaccine Training: General Overview of Immunization Best Practices for Healthcare Professionals

- It is a high-level overview of topics with links to detailed information, including:
 - Vaccine development and safety
 - Safety monitoring programs
 - Emergency Use Authorizations (EUAs)
 - Vaccine storage/handling
 - Vaccine preparation and administration
 - Reporting adverse events
- Information on each vaccine product will be added as each is authorized by FDA.



COVID-19 Vaccine Product-Specific Materials

- All vaccine products will have:
 - Vaccine preparation and administration summary
 - Storage and handling summary
 - Standing orders template for each product
- Vaccine A-specific materials include:
 - Temperature log and beyond use date tracking tool when using the shipping container for storage
 - Temperature logs for ultra-cold freezer unit
 - Beyond use date tracker labels for refrigerator storage

Note: This standing order template may be adapted as appropriate according to applicable laws, regulations, and policies within your jurisdiction.

Purpose

- To reduce morbidity and mortality from COVID-19 by ensuring the vaccine is stored and handled according to the criteria established by the Centers for Disease Control and Prevention (CDC).

Policy

- Where authorized under state law, the vaccine may be stored in a refrigerator (e.g., pharmacy refrigerator) and not in a freezer without the need for a separate storage container.

Procedure

- Assess personnel for COVID-19 symptoms and fever.
- No vaccination history with COVID-19 vaccine.
- If previously vaccinated, check the immunization record card for previous COVID-19 vaccine.
- A previous dose of COVID-19 vaccine is not a contraindication to a second dose.
- This vaccine is a 2-dose series. Separate the two doses.
- Screen for contraindications and precautions.
- Provide Emergency Use Authorization (EUA) information to patients with a copy of the information, see section 6 titled "Document."
- Prepare to Administer Vaccine.
- Choose the needle gauge, needle length, and 18 years of age: 1-inch needle is recommended.
- 19 years of age and older:

Sex and Weight of Patient	Needle Gauge
Female or male fewer than 130 lbs	22-25
Female or male 130-152 lbs	22-25

Female

Male 11

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

Female

Male 28

COVID-19 Vaccine BNT162b2, Pfizer Storage and Handling Toolkit

- Monitor temperatures using a digital data logger (DDL). See CDC's Vaccine Storage and Handling Toolkit COVID-19 Addendum for additional information.
- Check and record the minimum and maximum temperatures at the start of each workday. Document these temperatures in the min/max temperature log under the appropriate date.
- If DDL does not read min/max temperatures, then check and record the current temperature a minimum of 2 times per workday (at the start and end of the workday). Document these temperatures by putting an X in the row that corresponds to the higher temperature under the appropriate date.
- Save this record for 3 years, unless your state/local jurisdiction requires a longer time period.

For additional information, see the vaccine manufacturer's product information.

Month: _____ PIN Number: _____ Facility Name: _____

Day of the Month: _____

Min/Max Temperature: _____

Staff Initials: _____

Time: _____

Temperature below -40°C (below -40°F) or above 4°C (above 40°F)

60°C

41°C

42°C

43°C

44°C

45°C

46°C

47°C

48°C

49°C

50°C

51°C

52°C

53°C

54°C

55°C

56°C

57°C

58°C

59°C

60°C

61°C

62°C

63°C

64°C

65°C

66°C

67°C

68°C

69°C

70°C

71°C

72°C

73°C

74°C

75°C

76°C

77°C

78°C

79°C

80°C

81°C

82°C

83°C

- Vaccine storage issues develop:
1. Label the vaccine "Do Not Use" and store it under proper conditions as quickly as possible.
2. Complete the Vaccine Trouble Shooting Record. Do not discard and contact your jurisdiction's immunization program and the manufacturer.

in an ultra-cold freezer, shipping container, or see guidance below for each storage unit.

Before light regardless of when it is stored.

Age and temperatures using a digital data logger (DDL).

See CDC's Vaccine Storage and Handling Toolkit COVID-19 Addendum for additional information.

is delivered

arrive at a temperature between 80°C and -70°F in a thermal shipping container.

A signature will be required when the vaccine

container holds up to 1 cartons/bags.

contains 195 multidose vials (975 doses).

Check and record storage unit minimum and maximum temperatures at the start of each workday. If the DDL does not read min/max temperatures, then check and record the current temperature a minimum of 2 times per workday (at the start and end of the workday).

Save storage records for 3 years, unless your state/local jurisdiction requires a longer time period.

Each vial contains 5 doses after mixing.

The 0.9% normal saline preservative-free diluent will arrive separately from the vaccine.

Disable GPI temperature monitoring device following manufacturer's guidance.

Before mixing, COVID-19 vaccine (BNT162b2, Pfizer) vaccine may be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 5 days (120 hours). After 5 days (120 hours), remove any remaining vials from the unit. Contact the immunization program for additional guidance.

Storage labels are formatted to print on adhesive labels size 4"x3 1/2". We are unable to format to other size labels. If this size label is not available, print on paper and tape to container holding the vaccine.

1. Protect the vaccine from light by placing vial(s) in a resealable, opaque container such as an envelope or a plastic bag or a clear plastic bag lined with paper.

the vaccine.

for between 2°C and 8°C (36°F and 46°F).

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

COVID-19 Vaccine BNT162b2, Pfizer Storage and Handling Toolkit

in an ultra-cold freezer, shipping container, or see guidance below for each storage unit.

Before light regardless of when it is stored.

Age and temperatures using a digital data logger (DDL).

See CDC's Vaccine Storage and Handling Toolkit COVID-19 Addendum for additional information.

is delivered

arrive at a temperature between 80°C and -70°F in a thermal shipping container.

A signature will be required when the vaccine

container holds up to 1 cartons/bags.

contains 195 multidose vials (975 doses).

Check and record storage unit minimum and maximum temperatures at the start of each workday. If the DDL does not read min/max temperatures, then check and record the current temperature a minimum of 2 times per workday (at the start and end of the workday).

Save storage records for 3 years, unless your state/local jurisdiction requires a longer time period.

Each vial contains 5 doses after mixing.

The 0.9% normal saline preservative-free diluent will arrive separately from the vaccine.

Disable GPI temperature monitoring device following manufacturer's guidance.

Before mixing, COVID-19 vaccine (BNT162b2, Pfizer) vaccine may be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 5 days (120 hours). After 5 days (120 hours), remove any remaining vials from the unit. Contact the immunization program for additional guidance.

Storage labels are formatted to print on adhesive labels size 4"x3 1/2". We are unable to format to other size labels. If this size label is not available, print on paper and tape to container holding the vaccine.

1. Protect the vaccine from light by placing vial(s) in a resealable, opaque container such as an envelope or a plastic bag or a clear plastic bag lined with paper.

the vaccine.

for between 2°C and 8°C (36°F and 46°F).

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

COVID-19 Vaccine BNT162b2, Pfizer Storage and Handling Toolkit

in an ultra-cold freezer, shipping container, or see guidance below for each storage unit.

Before light regardless of when it is stored.

Age and temperatures using a digital data logger (DDL).

See CDC's Vaccine Storage and Handling Toolkit COVID-19 Addendum for additional information.

is delivered

arrive at a temperature between 80°C and -70°F in a thermal shipping container.

A signature will be required when the vaccine

container holds up to 1 cartons/bags.

contains 195 multidose vials (975 doses).

Check and record storage unit minimum and maximum temperatures at the start of each workday. If the DDL does not read min/max temperatures, then check and record the current temperature a minimum of 2 times per workday (at the start and end of the workday).

Save storage records for 3 years, unless your state/local jurisdiction requires a longer time period.

Each vial contains 5 doses after mixing.

The 0.9% normal saline preservative-free diluent will arrive separately from the vaccine.

Disable GPI temperature monitoring device following manufacturer's guidance.

Before mixing, COVID-19 vaccine (BNT162b2, Pfizer) vaccine may be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 5 days (120 hours). After 5 days (120 hours), remove any remaining vials from the unit. Contact the immunization program for additional guidance.

Storage labels are formatted to print on adhesive labels size 4"x3 1/2". We are unable to format to other size labels. If this size label is not available, print on paper and tape to container holding the vaccine.

1. Protect the vaccine from light by placing vial(s) in a resealable, opaque container such as an envelope or a plastic bag or a clear plastic bag lined with paper.

the vaccine.

for between 2°C and 8°C (36°F and 46°F).

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE

EXAMPLE



Resources: Talking to Patients about COVID-19 Vaccines

- Starting COVID-19 Vaccine Conversations Early
- Engaging in Effective COVID-19 Vaccine Conversations
- Answering Patients' Questions

The screenshot shows the CDC Vaccines & Immunizations website. The header includes the CDC logo, the text 'Centers for Disease Control and Prevention', and a search bar. The main navigation bar is green with the text 'Vaccines & Immunizations'. Below this, a breadcrumb trail reads 'CDC > Vaccines and Immunizations Home > COVID-19 Vaccination > For Healthcare Professionals'. The left sidebar contains a list of links: 'Vaccines and Immunizations Home', 'For Parents', 'For Adults', 'For Pregnant Women', 'For Healthcare Professionals', 'COVID-19 Vaccination', 'For Healthcare Professionals', 'Preparing to Provide COVID-19 Vaccines', 'Understanding and Explaining mRNA COVID-19 Vaccines', 'Talking to Patients about COVID-19 Vaccines' (highlighted), 'Making a Strong Recommendation for COVID-19 Vaccination', 'Answering Patients' Questions', 'COVID-19 Vaccination Planning', 'For Immunization Managers', 'For Specific Groups of People', and 'Basics and Common Questions'. The main content area is titled 'Talking to Patients about COVID-19 Vaccines' and contains three sections: 'Starting COVID-19 Vaccine Conversations Early', 'Engaging in Effective COVID-19 Vaccine Conversations', and 'Answering Patients' Questions'. Each section has a brief description and a link to a related resource. The footer includes the text 'Page last reviewed: November 2, 2020' and 'Content source: National Center for Immunization and Respiratory Diseases'.

★ Challenge: Staying Current

- Information changes quickly
- Sign up for e-mail alerts for COVID-19 vaccine webpages

Get Email Updates

To receive email updates about this page, enter your email address:


Your E-mail address here

[What's this?](#)

Submit

★ New COVID-19 vaccine website

www.chicago.gov/COVIDvax



The City of Chicago has been preparing since the pandemic started to make one or more COVID-19 vaccines available as soon as possible. There will be a phased roll-out of the COVID-19 vaccine with a very limited supply at the beginning, so healthcare workers will be prioritized, particularly those who treat COVID patients. Vaccine supply is expected to continually increase in the weeks and months that follow and it will then be made available to others. The Chicago Department of Public Health is working with partners at all levels, including hospitals, health care providers, and community leaders, on flexible COVID-19 vaccination programs that can accommodate different vaccines and scenarios.

Questions?



[**Chicago.gov/Health**](https://chicago.gov/Health)



[**HealthyChicago@cityofchicago.org**](mailto:HealthyChicago@cityofchicago.org)



[**@ChicagoPublicHealth**](https://www.facebook.com/ChicagoPublicHealth)



[**@ChiPublicHealth**](https://twitter.com/ChiPublicHealth)